e.l.f. Expands Global Reach with Retail Launches and Market Growth
e.l.f. is expanding the reach of its unique value proposition, powerhouse innovation and disruptive marketing engine, driven by growth in existing non-U.S. markets and consumer demand in new global regions. Currently, e.l.f. has a retail presence in 14 countries, with additional global distribution via eShopWorld. In the first quarter of Fiscal Year 2025, reported last month, non-U.S. markets represented 16% of e.l.f. Beauty’s total net sales and non-U.S. markets net sales grew 91% year-over-year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904617227/en/
e.l.f. is expanding global reach driven by growth in existing non-U.S. markets and consumer demand in new global regions. (Photo: Business Wire)
Part of e.l.f.’s international expansion strategy is partnering with leading global retailers and distributors who have the scale to make a strong and immediate impact and align with e.l.f.’s vision of positivity, inclusivity and accessibility. e.l.f. also engages with its community before entering a market – driving consumer demand and excitement.
“We see immense potential to make significant impact internationally, fueled by our commitment to make the best of beauty accessible to every eye, lip, face and skin concern,” said Tarang Amin, Chairman and CEO, e.l.f. Beauty. “Our approach is a combination of a disciplined sequential strategy with leading beauty retailers while meeting the call of our community where they are asking for our presence.”
In existing markets, e.l.f. is meeting community demand by tapping into both new and existing partners and continues to broaden its global reach by entering new markets:
- Germany: As previously announced, e.l.f. is expanding in Germany with its largest international retail launch to date in 1,600 ROSSMANN locations nationwide.
- U.K.: e.l.f. Cosmetics is now the No. 4 mass makeup brand as compared to No. 8 a year ago.* To build on this momentum, e.l.f. Cosmetics is gaining space in several hundred Boots and Superdrug locations this fall.
- Mexico: As previously announced, e.l.f. will debut in dozens of Sephora Mexico locations this fall, marking its re-entry in the country and its first time with Sephora Mexico. This strategic move helps address local demand for premium-quality products at accessible prices with universal appeal.
- Australia: e.l.f. recently expanded its existing distributor relationship in Australia by launching in Coles, marking the brand’s first venture into the country’s grocery channel. This fall, e.l.f. will also expand its presence in Priceline.
- Italy: e.l.f. Cosmetics entered Douglas last fall as the No. 1 makeup brand across mass and prestige in all existing doors and has stayed there.** To keep up the forward progress in Italy, e.l.f. Cosmetics will double the current store space by expanding into hundreds of additional Douglas locations this fall and will launch on Amazon this fall.
- Netherlands: e.l.f. Cosmetics has maintained the No. 1 mass makeup brand ranking in Etos since launch in April 2024.***
- Canada: e.l.f. Cosmetics has risen to the No. 4 mass makeup brand, up from No. 6 a year ago.
- Nordics: This fall, e.l.f. is excited to reveal that SÆTHER will serve as the exclusive distributor for e.l.f. in the Nordic region, with new launches anticipated in the following retailers: H&M, Matas, Kicks, Vita, Sokos and Lyko.
By partnering with key retailers and building strong connections with local communities, e.l.f. is well-positioned to continue its successful international growth strategy.
*Source: e.l.f. Cosmetics claim based on data reported by NielsenIQ through its Scantrack Service for the Mass Market Color Cosmetics category for the 12-week period ending June 15, 2024, for the GB market. Copyright © 2024, Nielsen Consumer, LLC.
** Source: Douglass, Italy, August 2024
*** Source: Etos, Netherlands, August 2024
About e.l.f. Beauty:
e.l.f. Beauty (NYSE: ELF) is fueled by a belief that anything is e.l.f.ing possible. We are a different kind of company that disrupts norms, shapes culture and connects communities, committed to positivity, inclusivity and accessibility. Our mission is clear: to make the best of beauty accessible to every eye, lip, face and skin concern. e.l.f. Cosmetics, e.l.f. SKIN, Keys Soulcare, Well People and NATURIUM are led by purpose, driven by results and elevated by our superpowers. e.l.f. Beauty has double Cruelty Free certifications from both Leaping Bunny and PETA, offers e.l.f. clean and vegan products, and proudly stands as the first beauty company to achieve Fair Trade certification across our supply chain. A kind heart is at the center of our ethos: We donate 2% of net profits to organizations that make positive impacts. Learn more at www.elfbeauty.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future, are forward-looking statements. Although e.l.f. Beauty believes that the expectations reflected in the forward-looking statements are reasonable, actual results and the timing of selected events may differ materially from those expectations. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things, the risks and uncertainties that are described in e.l.f. Beauty’s filings with the Securities and Exchange Commission. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date hereof. Except as required by law, e.l.f. Beauty assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904617227/en/
Contacts
Media:
Hannah Rubin
hrubin@elfbeauty.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom